John Choi

Biography

Dr. John Choi is a Venture Partner at Fidelity Growth Partners Asia and Fidelity Biosciences, where he is responsible for Fidelity’s healthcare portfolio, which includes Adagene. Dr. Choi has extensive experience as a healthcare investor, and executive and serial entrepreneur. He is a co-founder of Hua Medicine, another Fidelity company, as well as Pytho Capital, a research-oriented, life-science specialized hedge fund that invests in small-cap, public biotech companies. Before co-founding Pytho Capital, John was a Principal at the storied venture capital firm of Venrock Associates, the venture investing arm of the Rockefellers. During his tenure there, John focused on Venrock's biotechnology and medical device franchises, working actively with portfolio companies such as Coley Pharmaceuticals (acquired by Pfizer NYSE:PFE), Sirna Therapeutics (acquired by Merck NYSE: MRK), Celladon Corporation, and Princeton Lightwave. He was also previously involved with investments in Nanogram Devices Corporation (acquired by Wilson Greatbatch NYSE:GB), Targeted Genetics Corporation (NASDAQ:TGEN) and led the investment in Skinetics Biosciences (acquired by Sirna Therapeutics NASDAQ:RNAI). Prior to Venrock, he worked at the San Francisco offices of TVM Capital, an international venture capital firm with offices in the US and Europe. Before embarking on his business and investment career, John worked in academia. He previously served as a Resident in the Departments of Internal Medicine and Genetics at Baylor College of Medicine. He completed his doctoral thesis at Harvard Medical School conducting nuclear magnetic resonance (NMR) studies of human T-cell surface proteins CD2 and CD4. In addition to his Ph.D. in Biophysics from Harvard University, John received his M.D. from Cornell University Medical College, and his B.S. in Applied Math and Physics from Yale College.

Research Interest

Pharma